TBC Actor Pharmaceuticals Pty Ltd
Product name
TBC
Sponsor
Accepted date
Feb-2024
Active ingredients
abiraterone acetate, prednisolone
Proposed indication
Indicated for use for newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) and metastatic advanced prostate cancer (castration resistant prostate cancer, mCRPC)
Application type
B (new combination)
Publication date
Feb-2024